Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00103103 · ClinicalTrials.gov registry record · Phase 2
Bortezomib, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Stomach Cancer
A Phase 2 study, sponsored by California Cancer Consortium.
- Terminated
- Registry status
- Phase 2
- Development phase
NCT00103103: Clinical Trial Phase 2 study, sponsored by California Cancer Consortium.
NCT00103103 is a Phase 2 study that was terminated before completion, run by California Cancer Consortium. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00103103, a Phase 2 study, was terminated before completion, sponsored by California Cancer Consortium.
- TERMINATED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fluorouracil and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with fluorouracil and leucovorin may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving bortezomib together with fluorouracil and leucovorin works in treating patients with metastatic or unresectable stomach cancer.
Interventions
- DRUG fluorouracil
- DRUG leucovorin calcium
- DRUG bortezomib
Trial Details
| Field | Value |
|---|---|
| Start Date | 2005-03 |
| Est. Completion | 2005-08 |
| Phase | Phase 2 |
Why NCT00103103 stopped before completion
NCT00103103 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which fluorouracil is the first listed.
NCT00103103 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00103103 about?
NCT00103103 is a clinical study titled "Bortezomib, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Stomach Cancer". RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fluorouracil and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. G...
What is the current status of trial NCT00103103?
This trial is currently terminated. It is a Phase 2 study. The study started on 2005-03. Estimated completion is 2005-08.
What interventions are being tested in trial NCT00103103?
The interventions under investigation include: fluorouracil (DRUG), leucovorin calcium (DRUG), bortezomib (DRUG).
Who is sponsoring clinical trial NCT00103103?
This trial is sponsored by California Cancer Consortium, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia